Merck Gains Positive Regulatory Nods For Dulera And Brinavess

Merck received two pieces of good news from regulatory authorities within a few days - first an FDA approval for its asthma drug Dulera, then a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for its intravenous atrial fibrillation drug Brinavess